Yazar "Gorar, Suheyla" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome
    (Springer, 2014) Ademoglu, Esra Nur; Gorar, Suheyla; Carlioglu, Ayse; Yazici, Havva; Dellal, Fatma Dilek; Berberoglu, Zehra; Akdeniz, Derya
    Background Nesfatin-1 is a recently discovered neuropeptide derived from its precursor nucleobindin-2 (NUCB2) and has been implicated in the regulation of feeding and energy metabolism. It is located in the brain and also produced at the periphery and present in the plasma. However, its pathophysiological role in humans remains unknown. Polycystic ovary syndrome (PCOS) is commonly presented with obesity, insulin resistance, hyperandrogenemia and hirsutism. Aim To characterize serum nesfatin-1 levels in PCOS women and determine association of nesfatin-1 with metabolic parameters. Materials and methods It is a cross-sectional study of 55 PCOS and 28 healthy women matched in age, in a university hospital setting. Anthropometric, hormonal, metabolic parameters and nesfatin-1 blood levels were determined. Results Nesfatin-1 levels were significantly higher in PCOS group compared with the controls 371.43 +/- 2.50 versus 275.55 +/- 1.74 pg/mL. Multivariate logistic regression analysis that contains: nesfatin-1, body mass index and homeostasis model assessment index revealed significant correlation of nesfatin-1 with the existence of PCOS (p < 0.05). Conclusions Higher nesfatin-1 levels in PCOS women compared to control group may suggest a possibility that nesfatin-1 may play some role in the PCOS.
  • Küçük Resim Yok
    Öğe
    Serum nesfatin-1 levels are decreased in pregnant women newly diagnosed with gestational diabetes
    (Sbem-Soc Brasil Endocrinologia & Metabologia, 2017) Ademoglu, Esra Nur; Gorar, Suheyla; Keskin, Muge; Carlioglu, Ayse; Ucler, Rifki; Erdamar, Husamettin; Culha, Cavit
    Objective: To investigate serum nesfatin-1 levels at 24-28 weeks of pregnancy in women newly diagnosed with gestational diabetes and determine the association of nesfatin-1 with several metabolic parameters. Subjects and methods: Forty women newly diagnosed with gestational diabetes at 24-28 weeks of pregnancy and 30 healthy pregnant women matched in age and gestational week were included in this cross-sectional study. Serum nesfatin-1 levels were analyzed using ELISA, and the relationship between nesfatin-1 and several metabolic parameters were assessed. Results: Serum nesfatin-1 levels were found to be lower in women with gestational diabetes compared to the pregnant women in the control sample (p = 0.020). Multiple linear regression analysis revealed that nesfatin-1 was lower in participants with gestational diabetes independently from gestational age, BMI, HOMA-IR, fasting plasma glucose, and age. In correlation analysis, the only variable that was found to have a statistically significant correlation with nesfatin-1 was gestational age (p = 0.015, r = 0.30). Conclusion: Lower nesfatin-1 levels in women with gestational diabetes compared to the control group at 24-28 weeks of gestation draws attention to nesfatin-1 levels in gestational diabetes and motivates further research in this area.